Scientists have shared promising findings from a phase I clinical trial centred on an advanced stem cell therapy for repairing cornea damage.
The innovative therapy, known as cultivated autologous limbal epithelial cell transplantation (CALEC), demonstrates both safety and short-term efficacy in patients suffering from severe cornea damage caused by chemical burns.
Published in the journal Science Advances, the team’s study showcases the potential of CALEC in transforming the lives of patients previously deemed untreatable due to their extensive cornea injuries.